Global Drugs for Short Bowel Syndrome Market Growth: Industry Size, Analysis and Forecast

Report ID : 1312819 | Published : May 2025 | Study Period : 2023-2033 | Format : PDF + Excel

The market size of the Drugs For Short Bowel Syndrome Market is categorized based on Drug Type (Recombinant Human Growth Hormone, Glutamine, Antibiotics, Nutritional Supplements, Other Therapeutics) and Route of Administration (Oral, Intravenous, Subcutaneous, Other Routes) and End-User (Hospitals, Specialty Clinics, Home Care Settings, Pharmacies, Other End-Users) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The market size of Drugs For Short Bowel Syndrome Market, valued at $1.2 billion in 2023, is projected to reach $2.5 billion by 2033, expanding at a CAGR of 7.8% between 2024 and 2033. The report comprises various segments and analyzes significant trends and factors influencing market growth.

Short Bowel Syndrome is a problematic condition that occurs in an individual when there is partial surgical removal of small intestine or when it becomes non-functional. The remaining intestine leads to increased nutritional deficiency. Treatment of SBS has progressed over the years and now focuses more on volumetric pharmaceutical products aimed at deep absorption of nutrients and ameliorating life quality, thus creating an SBS Drug market. The medical advancements and innovations in treatment options enhance the SBS serving specialist physicians market.  

The systemic approach to treating SBS is currently multidisciplinary and is represented by a wide range of medicinal products - from hormonal treatments to dietary supplements. The growing SBS problem, because of the increasing number of surgeries for Crohn’s disease and intestinal ischemia, creates the need for effective drugs. Innovative therapies designed to relieve symptoms and address fundamental issues identified through comprehensive SBS research are being developed by many pharmaceutical companies resulting in potent market growth.

With the growth of understanding Short Bowel Syndrome, both from a patient and healthcare professional’s perspective, the importance of specialized market research is becoming critical. Grasping the intricacies related to the Drugs for Short Bowel Syndrome market will assist the stakeholders in making educated decisions, refining treatment approaches, and improving patient care. We, at Verified Industry Insights, strive to provide deep market analysis for evolving landscapes so our clients are prepared to tackle the challenges within the SBS therapeutic market.

 

ATTRIBUTES	DETAILS
STUDY PERIOD	2023-2033
BASE YEAR	2023
FORECAST PERIOD	2024-2033
HISTORICAL PERIOD	2023-2024
UNIT	VALUE (USD BILLION)
KEY COMPANIES PROFILED	AbbVie Inc., Takeda Pharmaceutical Company Limited, Shire (acquired by Takeda), MediGene AG, Sobi (Swedish Orphan Biovitrum), Eisai Co. Ltd., Fresenius Kabi AG, Bristol-Myers Squibb, Amgen Inc., Horizon Therapeutics, Acerus Pharmaceuticals Corporation
SEGMENTS COVERED	By Drug Type - Recombinant Human Growth Hormone, Glutamine, Antibiotics, Nutritional Supplements, Other Therapeutics By Route of Administration - Oral, Intravenous, Subcutaneous, Other Routes By End-User - Hospitals, Specialty Clinics, Home Care Settings, Pharmacies, Other End-Users By Geography - North America, Europe, APAC, Middle East Asia & Rest of World.

---

Drugs For Short Bowel Syndrome Market Dynamics

The Drugs For Short Bowel Syndrome Market is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.

Market Drivers

1. Technological Advancements
2. Increasing Consumer Demand
3. Regulatory Support
4. Globalization

Market Restraints

1. High Operational Costs
2. Regulatory Challenges
3. Market Saturation

Market Opportunities

1. Emerging Markets
2. Product Innovation
3. Strategic Partnerships

Market Challenges

1. Technological Disruptions
2. Supply Chain Issues
3. Changing Consumer Preferences

---

Key Players in the Drugs For Short Bowel Syndrome Market

This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.

• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Shire (acquired by Takeda)
• MediGene AG
• Sobi (Swedish Orphan Biovitrum)
• Eisai Co. Ltd.
• Fresenius Kabi AG
• Bristol-Myers Squibb
• Amgen Inc.
• Horizon Therapeutics
• Acerus Pharmaceuticals Corporation

---

Customization Options

Verified Industry Insights offers one of the following report customization options to our respectable clients :

Company Profiling

● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)

Competitive Benchmarking

● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research

Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@verifiedindustryinsights.com or call us at +1 743 222 5439

© 2024 Verified Industry Insights. All Rights Reserved